Removing barriers to participation in clinical trials, a conceptual framework and retrospective chart review study

Trials

Michael A Carducci¹  Dare Olatoye²  Marty S Kanarek⁴  Norma F Kanarek³ 

[1]Department of Oncology (Urologic Oncology), Johns Hopkins School of Medicine, Cancer Research Building I, Room 1M59, Baltimore, MA, USA

[2]Johns Hopkins School of Medicine, 733 North Broadway, Baltimore, MD, 21205-2196, USA

[3]Department of Oncology, Johns Hopkins School of Medicine, 615 North Wolfe Street, Baltimore, MD 21205, USA

[4]Department of Population Health Sciences, School of Medicine and Public Health and the Nelson Institute for Environmental Studies, University of Wisconsin-Madison, 610 North Walnut Street, Madison, WI, 53726, USA

关键词: Framework;    Disparities;    Barriers to clinical trials;    Prostate cancer;    Clinical trial accrual;    Clinical trials;    Respect for persons;    Beneficence;    Justice;   

Others  :  1095065
DOI  :  10.1186/1745-6215-13-237

 received in 2012-09-18, accepted in 2012-11-19,  发布年份 2012

【 摘 要 】

Background

Enrollment in interventional therapeutic clinical trials is a small fraction of all patients who might participate given reasonable access.

Methods

A hierarchical approach is utilized in measuring staged participation from trial availability to patient enrollment. Our framework suggests that concern for justice comes in the design and eligibility criteria for clinical trials; attention to beneficence is given in the eligibility and physician triage stages. The remaining four stages rely on respect for persons. An example is given where reasons for nonparticipation or barriers to participation in prostate cancer clinical trials are examined within the framework. In addition, medical oncology patients with an initial six month consultation are tracked from one stage to the next by race using the framework to assess participation comparability.

Results

We illustrated seven transitions from being a patient to enrollment in a clinical trial in a small study of prostate cancer cases who consulted SKCCC Medical Oncology Department in early 2010. Pilot data suggest transition probabilities as follows: 65% availability, 84% eligibility, 92% patient triage, 89% trials discussed, 45% patient interested, 63% patient consented, and 92% patient enrolled. The average transition probability was 77.7%. The average transition probability, patient-trial-fit was 50%; opportunity was 51%, and acceptance was 66.7%. Trial availability, patient interest and patient consented were three transitions that were below the average; none were statistically significant.

Conclusions

The framework may serve to streamline comprehensive reporting of clinical trial participation to the benefit of patients and the ethical conduct of clinical trials.

【 授权许可】

   
2012 Kanarek et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Sateren WB, Trimble EL, Abrams J, Brawley O, Breen N, Ford L, McCabe M, Kaplan R, Smith M, Ungerleider R, Christian MC: How sociodemographics, presence of oncology specialists, and hospital cancer programs affect accrual to cancer treatment trials. J Clin Oncol 2002, 20:2109-2117.
• [2]Al-Refaie WB, Vickers SM, Zhong W, Parsons H, Rothenberger D, Habermann EB: Cancer trials versus the real world in the United States. Ann Surg 2011, 254:438-443.
• [3]Baquet CR, Ellison GL, Mishra SI: Analysis of Maryland cancer patient participation in national cancer institute-supported cancer treatment clinical trials. J Clin Oncol 2008, 26:3380-3386.
• [4]Tejeda HA, Green SB, Trimble EL, Ford L, High JL, Ungerleider RS, Friedman MA, Brawley OW: Representation of African-Americans, Hispanics, and whites in national cancer institute cancer treatment trials. J Natl Cancer Inst 1996, 88:812-816.
• [5]Kanarek NF, Tsai HL, Metzger-Gaud S, Damron D, Guseynova A, Klamerus JF, Rudin CM: Geographic proximity and racial disparities in cancer clinical trial participation. J Natl Compr Canc Netw 2010, 8:1343-1351.
• [6]Onega T, Duell EJ, Shi X, Wang D, Demidenko E, Goodman D: Geographic access to cancer care in the U.S. Cancer 2008, 112:909-918.
• [7]Su SC, Kanarek N, Fox MG, Guseynova A, Crow S, Piantadosi S: Spatial analyses identify the geographic source of patients at a National Cancer Institute Comprehensive Cancer Center. Clin Cancer Res 2010, 16:1065-1072.
• [8]Martel CL, Li Y, Beckett L, Chew H, Christensen S, Davies A, Lam KS, Lau DH, Meyers FJ, O'Donnell RT, Richman C, Scudder S, Tanaka M, Tuscano J, Welborn J, Wun T, Gandara DR, Lara PN Jr: An evaluation of barriers to accrual in the era of legislation requiring insurance coverage of cancer clinical trial costs in California. Cancer J 2004, 10:294-300.
• [9]Castel P, Negrier S, Boissel JP: Why don't cancer patients enter clinical trials? A review. Eur J Cancer 2006, 42:1744-1748.
• [10]Grunfeld E, Zitzelsberger L, Coristine M, Aspelund F: Barriers and facilitators to enrollment in cancer clinical trials: qualitative study of the perspectives of clinical research associates. Cancer 2002, 95:1577-1583.
• [11]Lara PN Jr, Paterniti DA, Chiechi C, Turrell C, Morain C, Horan N, Montell L, Gonzalez J, Davis S, Umutyan A, Martel CL, Gandara DR, Wun T, Beckett LA, Chen MS Jr: Evaluation of factors affecting awareness of and willingness to participate in cancer clinical trials. J Clin Oncol 2005, 23:9282-9289.
• [12]Vickers AJ, Kramer BS, Baker SG: Selecting patients for randomized trials: a systematic approach based on risk group. Trials 2006, 7:30.
• [13]Lara PN Jr, Higdon R, Lim N, Kwan K, Tanaka M, Lau DH, Wun T, Welborn J, Meyers FJ, Christensen S, O’Donnell R, Richman C, Scudder SA, Tuscano J, Gandara DR, Lam KS: Prospective evaluation of cancer clinical trial accrual patterns: identifying potential barriers to enrollment. J Clin Oncol 2001, 19:1728-1733.
• [14]Schiller JH: Study design issues and early stage non-small cell lung cancer. Clin Cancer Res 2005, 11:5030s-5032s.
• [15]Go RS, Frisby KA, Lee JA, Mathiason MA, Meyer CM, Ostern JL, Walther SM, Schroeder JE, Meyer LA, Umberger KE: Clinical trial accrual among new cancer patients at a community-based cancer center. Cancer 2006, 106:426-433.
• [16]Proctor JW, Martz E, Schenken LL, Rainville R, Marlowe U: A screening tool to enhance clinical trial participation at a community center involved in a radiation oncology disparities program. J Oncol Pract 2011, 7:161-164.
• [17]Altman DG, Schulz KF, Moher D, Egger M, Davidoff F, Elbourne D, Gotzsche PC, Lang T: The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med 2001, 134:663-694.
• [18]Unger JM, Coltman CA Jr, Crowley JJ, Hutchins LF, Martino S, Livingston RB, Macdonald JS, Blanke CD, Gandara DR, Crawford ED, Albain KS: Impact of the year 2000 Medicare policy change on older patient enrollment to cancer clinical trials. J Clin Oncol 2006, 24:141-144.
• [19]The National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research: The Belmont report: ethical principles and guidelines for the protection of human subjects of research. Washington, DC: United States Department of Health, Education, and Welfare; 1979.
• [20]Emanuel EJ, Wendler D, Grady C: What makes clinical research ethical? JAMA 2000, 283:2701-2711.
• [21]Brawley OW: The study of accrual to clinical trials: can we learn from studying who enters our studies? J Clin Oncol 2004, 22:2039-2040.
• [22]Bubley GJ, Carducci M, Dahut W, Dawson N, Daliani D, Eisenberger M, Figg WD, Freidlin B, Halabi S, Hudes G, Hussain M, Kaplan R, Myers C, Oh W, Petrylak DP, Reed E, Roth B, Sartor O, Scher H, Simons J, Sinibaldi V, Small EJ, Smith MR, Trump DL, Vollmer R, Wilding G: Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 1999, 17:3461-3467.
• [23]Scher HI, Eisenberger M, D'Amico AV, Halabi S, Small EJ, Morris M, Kattan MW, Roach M, Kantoff P, Pienta KJ, Carducci MA, Agus D, Slovin SF, Heller G, Kelly W, Lange PH, Petrylak D, Berg W, Higano C, Wilding G, Moul JW, Partin AN, Logothetis C, Soule HR: Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 2004, 22:537-556.
• [24]Simon MS, Du W, Flaherty L, Philip PA, Lorusso P, Miree C, Smith D, Brown DR: Factors associated with breast cancer clinical trials participation and enrollment at a large academic medical center. J Clin Oncol 2004, 22:2046-2052.
• [25]Behrendt CE, Gehan EA: Treatment-subgroup interaction: an example from a published, phase II clinical trial. Contemp Clin Trials 2009, 30:279-281.
• [26]Kemeny MM, Peterson BL, Kornblith AB, Muss HB, Wheeler J, Levine E, Bartlett N, Fleming G, Cohen HJ: Barriers to clinical trial participation by older women with breast cancer. J Clin Oncol 2003, 21:2268-2275.
• [27]Sheldon JM, Fetting JH, Siminoff LA: Offering the option of randomized clinical trials to cancer patients who overestimate their prognoses with standard therapies. Cancer Invest 1993, 11:57-62.
• [28]Miller FG, Rosenstein DL: The therapeutic orientation to clinical trials. N Engl J Med 2003, 348:1383-1386.
• [29]Mannel RS, Walker JL, Gould N, Scribner DR Jr, Kamelle S, Tillmanns T, McMeekin DS, Gold MA: Impact of individual physicians on enrollment of patients into clinical trials. Am J Clin Oncol 2003, 26:171-173.
• [30]Meropol NJ, Egleston BL, Buzaglo JS, Benson AB 3rd, Cegala DJ, Diefenbach MA, Fleisher L, Miller SM, Sulmasy DP, Weinfurt KP: Cancer patient preferences for quality and length of life. Cancer 2008, 113:3459-3466.
• [31]Stiles CR, Johnson L, Whyte D, Nergaard TH, Gardner J, Wu J: Does increased patient awareness improve accrual into cancer-related clinical trials? Cancer Nurs 2011, 34:E13-19.
• [32]Shannon-Dorcy K, Drevdahl DJ: "I had already made Up My mind": patients and caregivers' perspectives on making the decision to participate in research at a US cancer referral center. Cancer Nurs 2011, 34:428-433.
• [33]Weinfurt KP, Castel LD, Li Y, Sulmasy DP, Balshem AM, Benson AB 3rd, Burnett CB, Gaskin DJ, Marshall JL, Slater EF, Schulman KA, Meropol NJ: The correlation between patient characteristics and expectations of benefit from phase I clinical trials. Cancer 2003, 98:166-175.
• [34]Biedrzycki BA: Factors and outcomes of decision making for cancer clinical trial participation. Oncol Nurs Forum 2011, 38:542-552.
• [35]Brown RF, Butow PN, Butt DG, Moore AR, Tattersall MH: Developing ethical strategies to assist oncologists in seeking informed consent to cancer clinical trials. Soc Sci Med 2004, 58:379-390.
• [36]Kass N, Taylor H, Fogarty L, Sugarman J, Goodman SN, Goodwin-Landher A, Carducci M, Hurwitz H: Purpose and benefits of early phase cancer trials: what do oncologists say? what do patients hear? J Empir Res Hum Res Ethics 2008, 3:57-68.
• [37]Kass NE, Sugarman J, Medley AM, Fogarty LA, Taylor HA, Daugherty CK, Emerson MR, Goodman SN, Hlubocky FJ, Hurwitz HI, Carducci M, Goodwin-Landher A: An intervention to improve cancer patients' understanding of early-phase clinical trials. IRB 2009, 31:1-10.
• [38]Ruckdeschel JC, Albrecht TL, Blanchard C, Hemmick RM: Communication, accrual to clinical trials, and the physician-patient relationship: implications for training programs. J Cancer Educ 1996, 11:73-79.
• [39]Meropol NJ, Buzaglo JS, Millard J, Damjanov N, Miller SM, Ridgway C, Ross EA, Sprandio JD, Watts P: Barriers to clinical trial participation as perceived by oncologists and patients. J Natl Compr Canc Netw 2007, 5:655-664.
• [40]Sulmasy DP, Astrow AB, He MK, Seils DM, Meropol NJ, Micco E, Weinfurt KP: The culture of faith and hope: patients' justifications for their high estimations of expected therapeutic benefit when enrolling in early phase oncology trials. Cancer 2010, 116:3702-3711.
• [41]Rasco DW, Xie Y, Yan J, Sayne JR, Skinner CS, Dowell JE, Gerber DE: The impact of consenter characteristics and experience on patient interest in clinical research. Oncologist 2009, 14:468-475.
• [42]Lee MM, Chamberlain RM, Catchatourian R, Hiang J, Kopnick M, Ray P, Vijayakumar S: Social factors affecting interest in participating in a prostate cancer chemoprevention trial. J Cancer Educ 1999, 14:88-92.
• [43]Sabesan S, Burgher B, Buettner P, Piliouras P, Otty Z, Varma S, Thaker D: Attitudes, knowledge and barriers to participation in cancer clinical trials among rural and remote patients. Asia Pac J Clin Oncol 2011, 7:27-33.
• [44]Stepan KA, Gonzalez AP, Dorsey VS, Frye DK, Pyle ND, Smith RF, Throckmorton TA, Villejo LA, Cantor SB: Recommendations for enhancing clinical trials education: a review of the literature. J Cancer Educ 2011, 26:64-71.
• [45]Daugherty CK: Impact of therapeutic research on informed consent and the ethics of clinical trials: a medical oncology perspective. J Clin Oncol 1999, 17:1601-1617.
• [46]Mulhall JP, Montorsi F: Evaluating preference trials of oral phosphodiesterase 5 inhibitors for erectile dysfunction. Eur Urol 2006, 49:30-37.
• [47]Wolf AM, Nasser JF, Schorling JB: The impact of informed consent on patient interest in prostate-specific antigen screening. Arch Intern Med 1996, 156:1333-1336.
• [48]Miller FG, Joffe S: Balancing access and evaluation in the approval of new cancer drugs. JAMA 2011, 305:2345-2346.
• [49]Agrawal M, Grady C, Fairclough DL, Meropol NJ, Maynard K, Emanuel EJ: Patients' decision-making process regarding participation in phase I oncology research. J Clin Oncol 2006, 24:4479-4484.
• [50]Klamerus JF, Bruinooge SS, Ye X, Klamerus ML, Damron D, Lansey D, Lowery JC, Diaz LA Jr, Ford JG, Kanarek N, Rudin CM: The impact of insurance on access to cancer clinical trials at a comprehensive cancer center. Clin Cancer Res 2010, 16:5997-6003.
• [51]Mills EJ, Seely D, Rachlis B, Griffith L, Wu P, Wilson K, Ellis P, Wright JR: Barriers to participation in clinical trials of cancer: a meta-analysis and systematic review of patient-reported factors. Lancet Oncol 2006, 7:141-148.
• [52]Schutta KM, Burnett CB: Factors that influence a patient's decision to participate in a phase I cancer clinical trial. Oncol Nurs Forum 2000, 27:1435-1438.
• [53]Wright JR, Crooks D, Ellis PM, Mings D, Whelan TJ: Factors that influence the recruitment of patients to phase III studies in oncology: the perspective of the clinical research associate. Cancer 2002, 95:1584-1591.